Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allovir Inc ALVR

Healthcare Biotechnology
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life... see more

Recent & Breaking News (NDAQ:ALVR)

INVESTOR ALERT: Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

Accesswire February 5, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR

Accesswire February 5, 2024

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire February 5, 2024

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Accesswire February 5, 2024

INVESTOR ALERT: Levi & Korsinsky Reminds AlloVir, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

Accesswire February 5, 2024

ALVR SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors Can Join the Class Action Lawsuit!

Accesswire February 5, 2024

INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir Lawsuit - ALVR

Accesswire February 4, 2024

NATIONALLY RANKED ROSEN LAW FIRM Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR

Newsfile February 4, 2024

AlloVir Deadline Reminder

Newsfile February 4, 2024

INVESTOR ALERT: Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

Accesswire February 4, 2024

ALVR SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors Can Join the Class Action Lawsuit!

Accesswire February 4, 2024

SHAREHOLDER ALERT: Potential Recovery for AlloVir, Inc. (ALVR) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

Accesswire February 3, 2024

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Accesswire February 2, 2024

ROSEN, LEADING TRIAL ATTORNEYS, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR

Newsfile February 2, 2024

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 2, 2024

SHAREHOLDER ALERT: Levi & Korsinsky Reminds AlloVir, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

Accesswire February 2, 2024

ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options

PR Newswire February 2, 2024

INVESTOR ALERT: Potential Recovery for AlloVir, Inc. (ALVR) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

Accesswire February 2, 2024

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Accesswire February 2, 2024

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of AlloVir, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024 - (NASDAQ: ALVR)

PR Newswire February 2, 2024